'Genetic profiling' and ovarian cancer therapy (Review)

Molecular Medicine Reports

Volumn 4, Issue 5, 2011, Pages 771-777

  Vella, Nadia ^a   Aiello, Marco ^a   Russo, Alessia Erika ^a   Scalisi, Aurora ^b   Spandidos, Demetrios A ^d   Toffoli, Giuseppe ^c   Sorio, Roberto ^c   Libra, Massimo ^a   Stivala, Franca ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b AUSL 3   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Biological therapy; Gene polymorphisms; Ovarian cancer

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BEVACIZUMAB; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE M1; INTERLEUKIN 8; IRINOTECAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL; PLATINUM; VASCULOTROPIN ANTIBODY; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; DNA POLYMORPHISM; GASTROINTESTINAL TOXICITY; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

FEMALE; HUMANS; OVARIAN NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 79960393247     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.512     Document Type: Review

References (56)

1. Bonadonna G, Robustelli della Cuna G and Valagussa P: Medicina Oncologica. 8th edition. Masson, Milan, pp1240-1257, 2007.
2. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxelin patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest oNcology Group and Gynecologic Oncology Group trial. Southwest Oncology Group; Gynecologic Oncology Group. J Clin Oncol 21: 2460-2465, 2003. (Pubitemid 46606325)
3. Pfisterer J, Weber B, Reuss A, et al: Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98: 1036-1045, 2006. (Pubitemid 44288151)
4. Weinshilboum R: Inheritance and drug response. N Engl J Med 348: 529-537, 2003.
5. Evans WE and McLeod Hl: Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549, 2003. (Pubitemid 36159890)
6. Goldstein DB: Pharmacogenetics in the laboratory and the clinic. N Engl J Med 348: 553-556, 2003.
7. Medeiros R, Pereira D, Afonso N, et al: Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8: 156-161, 2003. (Pubitemid 36897285)
8. Germann UA: P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944, 1996.
9. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993. (Pubitemid 23237876)
10. Kamazawa S, Kigawa J, Kanamori Y, et al: Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86: 171-176, 2002. (Pubitemid 34953500)
11. Penson RT, Oliva E, Skates SJ, et al: Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106, 2004. (Pubitemid 38429555)
12. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000. (Pubitemid 30183327)
13. Marzolini C, Paus E, Buclin T and Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75: 13-33, 2004. (Pubitemid 38130115)
14. Sakaeda T, Nakamura T and Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25: 1391-1400, 2002. (Pubitemid 39663152)
15. Pauli-Magnus C and Kroetz DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21: 904-913, 2004.
16. Tanabe M, Ieiri I, Nagata N, et al: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137-1143, 2001. (Pubitemid 32472514)
17. Gréen H, Söderkvist P, Rosenberg P, Horvath G and Peterson C: Mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12: 854-859, 2006. (Pubitemid 43259868)
18. Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA and Peterson C: Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104: 130-137, 2009.
19. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194, 2001. (Pubitemid 32751614)
20. Itamochi H, Kigawa J, Sultana H, et al: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 93: 723-728, 2002. (Pubitemid 34846281)
21. Yokoyama Y, Sato S, Fukushi Y, et al: Significance of multidrug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25: 387-394, 1999. (Pubitemid 30028827)
22. Arts HJ, Katsaros D, de Vries EG, et al: Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5: 2798-2805, 1999. (Pubitemid 29493954)
23. Ueland PM, Hustad S, Schneede J, et al: Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22: 195-201, 2001. (Pubitemid 32244306)
24. Chiusolo P, Reddiconto G, Casorelli I, et al: Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13: 1915-1918, 2002.
25. Toffoli G, Russo A, Innocenti F, et al: Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103: 294-299, 2003. (Pubitemid 36076421)
26. Ulrich CM, Yasui Y, Storb R, et al: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98: 231-234, 2001.
27. Urano W, Taniguchi A, Yamanaka H, et al: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12: 183-190, 2002. (Pubitemid 34596782)
28. Chiang PK, Gordon RK, Tal J, et al: S-Adenosylmethionine and methylation. FASEB J 10: 471-480, 1996. (Pubitemid 26120322)
29. Calvert H: Folate status and the safety profile of antifolates. Semin Oncol 29: 3-7, 2002.
30. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nature Rev Drug Disc 4: 307-320, 2005. (Pubitemid 41130944)
31. Guminksi AD, Harnett PR and deFazio A: Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol 3: 312-318, 2002. (Pubitemid 34546449)
32. Altaha R, Liang X, Yu JJ, et al: Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 14: 959-970, 2004.
33. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
34. Ferry KV, Hamilton TC and Johnson SW: Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF. Biochem Pharmacol 60: 1305-1313, 2000.
35. Dabholkar M, Bostick-Bruton F and Weber C: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517, 1992.
36. Dabholkar M, Vionnet J, Bostick-Bruton F, et al: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994. (Pubitemid 24251002)
37. Yu JJ, Lee KB, Mu C, et al: Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16: 555-560, 2000.
38. Kang S, Ju W, Kim JW, et al: Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38: 320-324, 2006. (Pubitemid 44033245)
39. Smith S, Su D, Rigault de la Longrais IA, et al: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 25: 5172-5179, 2007. (Pubitemid 350232247)
40. Toiyama Y, Inoue Y, Hiro J, et al: The range of optimal concentration and mechanisms of paclitaxel in radio-enhancement in gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 59: 733-742, 2007. (Pubitemid 46440595)
41. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R and Siffert W: The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res 18: 343-347, 2010.
42. Watson CJ, Webb NJ, Bottomley MJ and Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12: 1232-1235, 2000. (Pubitemid 30611801)
43. Stevens A, Soden J, Brenchley PE, Ralph S and Ray DW: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63: 812-816, 2003. (Pubitemid 36231981)
44. Li L, Wang L, Zhang W, et al: Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 24: 1973-1979, 2004.
45. Bamberger ES and Perrett CW: Angiogenesis in epithelial ovarian cancer. Mol Pathol 55: 348-359, 2002.
46. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S and Schroeder W: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 16: 183-189, 2006.
47. Schultheis AM, Lurje G, Rhodes KE, et al: Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophospamide and bevacizumab. Clin Cancer Res 14: 7554-7563, 2008.
48. Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B and Prontera C: Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res 19: 1401-1405, 1999. (Pubitemid 29257466)
49. Rustin GJ: Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21: 187-193, 2003.
50. Rustin GJ, Quinn M, Thigpen T, et al: Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96: 487-488, 2004. (Pubitemid 38443654)
51. Stephens M, Smith NJ and Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989, 2001. (Pubitemid 32289743)
52. Stephens M and Scheet P: Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76: 449-462, 2005. (Pubitemid 40250525)
53. Steffensen KD, Waldstrøm M, Brandslund I and Jakobsen A: The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 117: 109-116, 2010.
54. Khrunin AV, Moisseev A, Gorbunova V and Limborska S: Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10: 54-61, 2010.
55. Chen ZP, Malapetsa A, Monks A, et al: Nucleotide excision repair protein levels vis-a-vis anticancer drug resistance in 60 human tumor cell lines. Ai Zheng 21: 233-239, 2002.
56. Saldivar JS, Lu KH, Liang D, et al: Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107: S223-S229, 2007. (Pubitemid 47487477)